Peijia Medical (HKG:9996)'s registration application for the TaurusTrio Transcatheter Aortic Valve (TAV) system has been accepted by China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.
The TaurusTrio TAV system, which is developed and manufactured by the company based on the exclusive license obtained from JenaValve Technology, is designed to treat patients with native symptomatic severe aortic regurgitation through transfemoral access.